|
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Clinical research trials and R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy. R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy clinical trial. Participants oftentimes recieve the most expert healthcare available for their R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy  R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
For Condition: recurrent breast cancer,stage 4 breast cancer
Status: No longer recruiting
Sponsor(s): EORTC Breast Cancer Cooperative Group , EORTC New Drug Development Group,National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining R101933 with paclitaxel or docetaxel may reduce resistance to the drug and allow the tumor cells to be killed. PURPOSE: Phase II trial to study the effectiveness of combining R101933 with either paclitaxel or docetaxel in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy.
Details: OBJECTIVES: - Determine the activity of R101933 in combination with paclitaxel or docetaxel in terms of response to treatment and level of clinical benefit in patients with taxane-refractory metastatic breast cancer. - Determine the safety of this regimen in these patients. - Determine the acute side effects in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive R101933 IV over 1 hour immediately followed by paclitaxel IV over 3 hours or docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity. Patients who have no disease progression after 7 courses may continue with treatment at the investigator's discretion. Patients are followed every 6 weeks until disease progression. PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic breast cancer - Received at least 2 prior courses of paclitaxel-based chemotherapy at doses between 175-200 mg/m2 (given over 3 hours every 3 weeks) or docetaxel-based chemotherapy at doses between 75-100 mg/m2 (given over 1 hour every 3 weeks) as most recent anticancer therapy - Evidence of disease resistance - Progressive disease as best response OR - Transient response or disease stabilization followed by progression during taxane-based treatment - Disease progression on a combination of a taxane and another cytotoxic agent allowed - Unidimensionally measurable disease - At least 1 target lesion that clearly progressed or developed during prior taxane therapy - Lesions stable or responsive to prior taxane therapy are not considered target lesions - Lesions that have been irradiated within the past 3 months are not considered target lesions unless they have clearly progressed or appeared since radiotherapy - No bone metastases as only site of measurable disease - No rapidly progressive visceral metastases - No symptomatic CNS metastases - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Not specified Menopausal status: - Not specified Performance status: - WHO 0-2 Life expectancy: - Not specified Hematopoietic: - Neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present) Renal: - Creatinine no greater than 1.5 times ULN - Calcium normal Cardiovascular: - LVEF normal by echocardiogram (ECG) or MUGA scan - QTc less than 450 sec on baseline ECG - No prior clinically significant arrhythmias requiring treatment - No cardiac infarction - No atrial ventricular enlargement or hypertrophy Other: - No prior toxicity to paclitaxel that would preclude study dose and schedule - Sodium, potassium, chloride, and bicarbonate normal - No pre-existing neuropathy greater than grade 2 - No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix, contralateral breast cancer, or nonmelanoma skin cancer or cancer that has been in remission for more than 5 years - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent anticancer biologic agents Chemotherapy: - See Disease Characteristics - No more than 8 weeks since last course of prior taxane-based chemotherapy - No more than 2 prior chemotherapy regimens for metastatic breast cancer - No other concurrent anticancer chemotherapy Endocrine therapy: - No concurrent anticancer hormonal therapy Radiotherapy: - See Disease Characteristics - No concurrent radiotherapy Surgery: - Not specified Other: - No prior multi-drug resistance inhibitor - No new anticancer therapy initiation since last course of prior taxane-based chemotherapy - No concurrent angiotensin converting enzyme inhibitor and/or drugs that may prolong the QTc interval - No other concurrent anticancer therapy - Concurrent bisphosphonates for treatment and prevention of bony metastases allowed provided drugs were initiated prior to study (treatment of hypercalcemia due to malignancy allowed regardless of time of initiation)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MartinePiccart-Gebhart, Study Chair, Institut Jules Bordet
Institut Jules Bordet
Brussels, , B-1000
Belgium
CRLCC Nantes - Atlantique
Nantes-Saint Herblain, , 44805
France
Additional Information:
Study ID Numbers: CDR0000069143; ECSG-EORTC-16004,IDBBC-10003,EORTC-16004
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00028873
Other Recurrent Breast Cancer Studies:
1. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
2. Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer
3. Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
4. Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
5. CP-724,714 in Treating Patients With Metastatic Breast Cancer
Related Studies:
Other recurrent breast cancer Clinical Trials
Other Clinical Trials
Other Brussels Clinical Trials
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
|
|
|
|
|
|
|
|
